X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Under the terms of the agreement, ASK Pharm will have exclusive rights to develop, manufacture and commercialize CGS-200-5 for the Greater China region. Topical CGS-200-5 has clinically been shown to significantly reduce OA knee pain.
Lead Product(s): Capsaicin
Therapeutic Area: Musculoskeletal Product Name: CGS-200-5
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aosaikang Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement April 07, 2022
Details:
The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label.
Lead Product(s): Capsaicin
Therapeutic Area: Neurology Product Name: Qutenza
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2021
Details:
LivRelief is a growing line of cannabis-infused topical creams created using natural ingredients which utilize a proprietary transdermal delivery system, allowing cannabinoids to reach targeted areas and designed for deep penetration.
Lead Product(s): Capsaicin,Cannabidiol
Therapeutic Area: Musculoskeletal Product Name: LivRelief
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harvest One Cannabis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 28, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
